ClinicalTrials.gg
Active, not recruitingNCT02264678Updated Jul 24, 2026

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

A Phase 1 interventional study of Administration of ceralasertib and Administration of ceralasertib in combination with olaparib in Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer, sponsored by AstraZeneca. Active, not recruiting at 28 sites in 4 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
358
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies in Ovarian Neoplasms by AstraZeneca — 8 open to participants now, 20 under way, 6 of them phase 3. Ovarian Neoplasms · AstraZeneca.

Enrollment
10th of 47
358 · median 181
Started
2014
with 2 others
Phase 1
15 of 70
2 open now
Primary completion
2025-03
later than 4 of 19 live
Registered
16th of 70
by date

Among the 70 studies in Ovarian Neoplasms by AstraZeneca, this one is the 10th largest by enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2014, is one of 15 in phase 1, reaches primary completion later than 4 of the 19 other live ones, and was the 16th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

8 of the 70 studies in Ovarian Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Ovarian Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced malignancies. The study design allows an investigation of optimal combination dose of ceralasertib with other anti-cancer treatments, with intensive safety monitoring to ensure the safety of the patients. The initial combination to be investigated is ceralasertib with carboplatin. The second combination to be investigated is ceralasertib with Olaparib. The third combination to be investigated is ceralasertib with durvalumab. The fourth module will investigate the effect of food on ceralasertib absorption and the effect of ceralasertib on ECG parameter. The fifth module to be investigated is ceralasertib with AZD5305.

Read the detailed description

This is a modular, phase I, two part, open-label, multicentre study of ceralasertib, administered orally, in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced/metastatic solid malignancies. The study design allows an escalation of the dose of ceralasertib in combination with the standard dose and schedule of either cytotoxic chemotherapies and/or novel anti-cancer agents, with intensive safety monitoring to ensure the safety of the patients. There are two parts to each combination module of this study; part A, dose escalation and an optional part B, cohort expansions in particular patient groups. The initial combination module will be with Carboplatin (module 1). The second combination will be with Olaparib (module 2). The third combination will be with durvalumab (module 3), the fourth combination will be AZD5305 (Module 5). The option to start further combination modules will be the decision of the Safety Review Committee (SRC), based on emerging preclinical data and, safety and tolerability information from the initial combination. Combinations of ceralasertib with novel anti-cancer agents may also be explored. Once a minimally biologically active dose of ceralasertib, for that combination module, has been identified from part A of that module, the SRC may decide to commence part B if deemed to be necessary. This may include cohort expansions of specific patient groups to explore preliminary anti-tumour activity or the effect of food or particular drug combinations on drug pharmacokinetics. The fourth module will investigate the effect of food on ceralasertib absorption and whether ceralasertib has an effect on QT.

03

Conditions studied

  • Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Browse trials for

Keywords

  • ATM deficient, ATM proficient, HER2 negative, Breast, Gastric, Head & Neck, Lung, Ovarian
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Principal Inclusion criteria:

  • Aged at least 18
  • The presence of a solid malignant tumour that is not considered appropriate for further standard treatment
  • Module 2 Part B study expansions, and Module 3: patients must have a tumour at least 1 cm in size that can be measured using a CT or MRI scan
  • Module 2 Part B All (except B5): No previous treatment with PARP inhibitor.
  • Module 2 Part B1 Study expansion: advanced gastric adenocarcinoma (including GEJ) patients with ATM deficient tumours
  • Module 2 Part B2 Study expansion: advanced gastric adenocarcinoma (including GEJ) patients with ATM proficient tumours
  • Module 2 Part B3 Study expansion: Second or thrid line negative breast cancer
  • Module 2 Part B4 Study expansion: Second or triple negative breast cancer (TNBC)
  • Module 2 Part B5 Study expansion: BRCAm or RAD51C/Dm or PALB2m or HRD positive status ovarian cancer patient who are Platinum Sensitive and have previously progressed on a licensed PARPi
  • Module 3: advanced recurrent or non-small cell lung cancer, or head and neck squamous cell carcinoma
  • Module 4: any advanced solid tumours except gastric, gastro-oesophageal, oesophageal or colorectal cancer with a small bowel resection
  • Module 4: Ability to comply with an overnight fast of at least 10 hours prior to dosing and 4 hours after dosing as mandated, and ability to eat a high fat meal as mandated
  • Module 5 All: Ovarian fallopian tube or primary peritonial cancer, previous treatment with PARP inhibitor, platinum-sensitive relapsed ovarian cancer
  • Module 5 Part B: known or suspected BRCA mutation, PALB2 mutation, RAD51C/D mutation or HRD positive status

Principal exclusion criteria

  • A diagnosis of ataxia telangiectasia
  • Prior exposure to an ATR inhibitor
  • Bad reaction to ceralasertib
  • Module 2: for treatment with olaparib
  • Module 3: Contra-indicated for treatment with durvalumab
  • Module 4: Mean resting interval (QTc) >470 msec or history of familial long QT syndrome.
  • Module 4: Patients with type I or type II diabetes
  • Module 5: Known to PARP including AZD5305
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
358 participants (actual)

Study arms

  • Experimental
    Module 2 Part A1

    Module 2 Part A1: ascending doses of ceralasertib will be administered alone to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD) to take into Module 2 Part A2.

    Drug: Administration of ceralasertib

  • Experimental
    Module 2 Part A2

    Module 2 Part A2: ascending doses of ceralasertib will be administered in combination with olaparib to patients to define the dose, frequency and schedule of ceralasertib and olaparib to take into Module 2 Part B.

    Drug: Administration of ceralasertib in combination with olaparib

  • Experimental
    Module 2 Part B1

    Module 2 Part B1: Patients with second line 'ATM deficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.

    Drug: Administration of ceralasertib in combination with olaparib

  • Experimental
    Module 2 Part B2

    Module 2 part B2: Patients with second line 'ATM proficient' gastric adenocarcinoma including GEJ adenocarcinoma will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.

    Drug: Administration of ceralasertib in combination with olaparib

  • Experimental
    Module 2 Part B3

    Module 2 Part B3: Patient with second or third line breast cancer with BRCA mutations (somatic or germline), excluding HER2 positive breast cancer will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.

    Drug: Administration of ceralasertib in combination with olaparib

  • Experimental
    Module 2 Part B4

    Module Part B4: Patients with second or third line triple negative breast cancer with no known BRCA mutations. This expansion will be enriched for patients with disease harbouring a HRR-related gene mutation (HRRm) will receive ceralasertib with olaparib, at dose, frequency and schedule recommended from Module 2 Part A2.

    Drug: Administration of ceralasertib in combination with olaparib

  • Experimental
    Module 3 Part A

    Module 3 Part A: cohort escalation of ceralasertib in combination with durvalumab in HNSCC or NSCLC patients to define the dose, frequency and schedule of ceralasertib and durvalumab to take into Module 3 Part B. Additionally, Module 3 Part A will include a serial tumour biopsy cohort to evaluate the Proof of Mechanism of ceralasertib in HNSCC and NSCLC patients.

    Drug: Administation of ceralasertib in combination with durvalumab

  • Experimental
    Module 3 Part B

    Module 3 Part B: cohort expansions of ceralasertib in combination with durvalumab in HNSCC or NSCLC patients at dose, frequency and schedule from Module 3 Part A.

    Drug: Administation of ceralasertib in combination with durvalumab

  • Experimental
    Module 2 Part B5

    Patients with BRCA mutant or RAD51C/D mutant (either germline or somatic) or HRD-positive status epithelial ovarian, fallopian tube, or primary peritoneal cancer according to local testing. Patients must be platinum sensitive and previously progressed on a licensed PARPi. The cohort will be split into 2 groups: Cohort 1 - without intervening chemotherapy following progression on a PARPi, Cohort 2 - with intervening chemotherapy following progression on a PARPi. Patients will receive ceralasertib and olaparib, at the RP2D dose, frequency and schedule established from Module 2 Part A2.

    Drug: Administration of ceralasertib in combination with olaparib

  • Experimental
    Module 4 (FE/QT)

    Ceralasertib monotherapy will be administered on a number of days during Cycle 0 to assess the effect of food on ceralasertib absorption and effect of ceralasertib on ECG parameters under various conditions (fasted, fed, steady state). From C1 onwards, patients who participated in C0 will be allocated to either ceralasertib in combination with olaparib or durvalumab, or ceralasertib monotherapy and assessed for safety.

    Drug: Administration of ceralasertib monotherapy · Drug: Administration of ceralasertib and olaparib · Drug: Administration of ceralasertib and durvalumab

  • Experimental
    Module 5 Part A

    Module 5 Part A: ascending doses of ceralasertib will be administered in combination with AZD5305 to patients to define the MTD, RP2D. In case this first dose level is not tolerated, alternative schedules will be evaluated.

    Drug: Administration of ceralasertib in combination with AZD5305

  • Experimental
    Module 5 Part B

    Module 5 Part B: cohort expansions of ceralasertib in combination with AZD5305 in ovarian patients at dose, frequency and schedule from Module 5 Part A.

    Drug: Administration of ceralasertib in combination with AZD5305

  • Experimental
    Module 1 Part A

    Module 1 Part A: ascending doses of ceralasertib in combination with carboplatin AUC5 will be administered to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD).

    Drug: Administration of ceralasertib in combination with carboplatin

  • Experimental
    Module 1 Part B

    Module 1 Part B: patients with advanced lung adenocarcinoma with low expression of ATM will receive ceralasertib and carboplatin, at the dose, frequency and schedule recommended from Module 1 Part A.

    Drug: Administration of ceralasertib in combination with carboplatin

Interventions

  • DrugAdministration of ceralasertib

    An oral formulation of ceralasertib will be used. In Module 2 Part A1, patients will receive a single dose of ceralasertib on Day 1, followed by 4 to 6 days washout, before multiple dosing.

  • DrugAdministration of ceralasertib in combination with olaparib

    An oral formulations of ceralasertib and olaparib will be used. In Module 2 Part A2, patients will receive either a single or twice daily dose of ceralasertib followed by 4 to 6 days washout, before multiple dosing with ceralasertib and olaparib. In Module 2 Part B, patients will receive ceralasertib and olaparib at the dose, frequency and schedule recommended from Module 2 Part A2. Cycle 0 may be omitted at the discretion of the sponsor.

  • DrugAdministation of ceralasertib in combination with durvalumab

    An oral formulation of ceralasertib will be used. Durvalumab is given via IV infusion. In Module 3 Part A, patients will receive an initial single dose of ceralasertib on Day 1, followed by multiple dosing in combination with durvalumab. In Module 3 Serial Tumour Biopsy Extension and Part B expansion cohorts, patients will receive ceralasertib at the dose, frequency and schedule recommended from Module 3 Part A, in combination with durvalumab.

  • DrugAdministration of ceralasertib monotherapy

    Module 4 Part A and Module 4 Part B Cohort 3: During C0, patients will receive ceralasertib monotherapy orally once a day on 3 non-consecutive days and ceralasertib twice a day on 5 consecutive days. After the patients have completed C0 (Part A) they may transition to Module 4 Part B cohort 3 where they will continue to receive ceralasertib monotherapy

  • DrugAdministration of ceralasertib and olaparib

    Module 4 Part B Cohort 1: After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with olaparib as decided by the investigator.

  • DrugAdministration of ceralasertib and durvalumab

    Module 4 Part B Cohort 2: After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with durvalumab as decided by the investigator.

  • DrugAdministration of ceralasertib in combination with AZD5305

    An oral formulations of ceralasertib and AZD5305 will be used. In Module 5 Part A, patients will receive a single dose of ceralasertib on cycle 0 Day 1 as per dose level cohort. In Module 5 Part B, patients will receive ceralasertib and AZD5305: C1 onwards (as per dose level cohort allocated).

  • DrugAdministration of ceralasertib in combination with carboplatin

    An oral formulation of ceralasertib will be used. In Module 1 Part A, patients will receive a single dose of ceralasertib on Day 1, followed by multiple dosing in combination with carboplatin. A maximum of 6 cycles (21 days per cycle) of treatment will be given. In Module 1 Part B, patients will receive ceralasertib and carboplatin at the dose, frequency and schedule recommended from Module 1 Part A.

This study also gives Durvalumab, Olaparib, Ceralasertib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. The number of subjects with adverse events/serious adverse events

    Number of patients with adverse events and with serious adverse events including abnormal clinical observations, DLT, abnormal Electrocardiogram (ECG) parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline.

    Time frame: From baseline until 28 days after discontinuation of study treatment for Module 1, 2 and 5 or until 90 days after discontinuation of study treatment for Module 3 and 4

  2. Module 4 only: Effect of food on ceralasertib absorption by Intensive PK assessments after a single oral dose of ceralasertib (Part A)

    Intensive PK sampling at defined timepoints to measure Geometric mean and 90% CI for the ratio of fed: fasted in area under the plasma concentration time curve from zero to the last measurable time point (AUC0-t), area under the plasma concentration time curve from zero to infinity (AUC)

    Time frame: From 0h to 24h on Day 2 and Day15 in Cycle 0 (Part A) - Cycle 0 is 15 days

  3. Module 4 only: Effect of ceralasertib on ECG parameters (HR, PR, QRS and QTcF) by ECG recordings

    Change from baseline HR, PR, QRS and QTcF (ΔHR, ΔPR, ΔQRS and ΔQTcF) Categorical outliers for QTcF, HR, PR, and QRS Frequency of treatment emergent T and U wave abnormalities If a substantial HR effect is observed (i.e., the absolute value of the largest least squares \[LS\] mean ΔHR is greater than 10bpm in the by-time point analysis), other correction methods such as individualised and optimised individualised HR corrected QT interval (QTcI) will be explored and compared. The method that removes the HR dependence of the QT interval most efficiently will be chosen as the primary correction method.

    Time frame: From 0h to 24h on Day 2, Day 8 and Day15 in Cycle 0 (Part A) - Cycle 0 is 15 days

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of ceralasertib

    Blood samples will be collected to assess plasma concentration of ceralasertib at a series of time points to derive Cmax.

    Time frame: At predefined intervals throughout the ceralasertib treatment period (approximately 8 weeks for Module 1 and 16 weeks + IP disc. for Module 2+3)

  2. Time to observed Cmax (Tmax) for ceralasertib

    Blood samples will be collected to assess plasma concentration of ceralasertib at a series of time points to derive Tmax.

    Time frame: At predefined intervals throughout the ceralasertib treatment period (approximately 8 weeks for Module 1 and 16 weeks + IP disc. for Module 2+3)

  3. Area under the plasma concentration-time curve (AUC) for ceralasertib

    Blood samples will be collected to assess plasma concentration of ceralasertib at a series of time points to derive AUC.

    Time frame: At predefined intervals throughout the ceralasertib treatment period (approximately 8 weeks for Module 1 and 16 weeks + IP disc. for Module 2+3)

  4. Maximum Observed Plasma Concentration (Cmax) of Carboplatin

    Blood samples will be collected to assess plasma concentration of Carboplatin at a series of time points to derive Cmax.

    Time frame: At predefined intervals throughout the Carboplatin treatment period (approximately 4 weeks for Module 1)

  5. Time to observed Cmax (Tmax) for Carboplatin

    Blood samples will be collected to assess plasma concentration of Carboplatin at a series of time points to derive Tmax.

    Time frame: At predefined intervals throughout the Carboplatin treatment period (approximately 4 weeks for Module 1)

  6. Area under the plasma concentration-time curve (AUC) for Carboplatin

    Blood samples will be collected to assess plasma concentration of Carboplatin at a series of time points to derive AUC.

    Time frame: At predefined intervals throughout the Carboplatin treatment period (approximately 4 weeks for Module 1)

  7. Maximum Observed Plasma Concentration (Cmax) of Olaparib

    Blood samples will be collected to assess plasma concentration of Olaparib at a series of time points to derive Cmax.

    Time frame: At predefined intervals throughout the Olaparib treatment period (approximately 12 weeks for Module 2)

  8. Time to observed Cmax (Tmax) for Olaparib

    Blood samples will be collected to assess plasma concentration of Olaparib at a series of time points to derive Tmax.

    Time frame: At predefined intervals throughout the Olaparib treatment period (approximately 12 weeks for Module 2)

  9. Area under the plasma concentration-time curve (AUC) for Olaparib

    Blood samples will be collected to assess plasma concentration of Olaparib at a series of time points to derive AUC.

    Time frame: At predefined intervals throughout the Olaparib treatment period (approximately 12 weeks for Module 2)

  10. Maximum Observed Plasma Concentration (Cmax) of durvalumab

    Blood samples will be collected to assess plasma concentration of durvalumab at a series of time points to derive Cmax.

    Time frame: At predefined intervals throughout the durvalumab treatment period (approximately 28 weeks + 90days post IP disc. for Module 3)

  11. Time to observed Cmax (Tmax) for durvalumab

    Blood samples will be collected to assess plasma concentration of durvalumab at a series of time points to derive Tmax.

    Time frame: At predefined intervals throughout the durvalumab treatment period (approximately 28 weeks + 90days post IP disc. for Module 3)

  12. Area under the plasma concentration-time curve (AUC) for durvalumab

    Blood samples will be collected to assess plasma concentration of durvalumab at a series of time points to derive AUC.

    Time frame: At predefined intervals throughout the durvalumab treatment period (approximately 28 weeks + 90days post IP disc. for Module 3)

  13. Assessment of pharmacodynamic biomarker changes

    Evaluation of ceralasertib activity in the tumour by assessment of pharmacodynamic biomarker changes which may include, but are not limited to functional ATR inhibition, ctDNA and CTCs.

    Time frame: Biopsies of tumour at baseline and last day of dosing

  14. Best objective response

    Best objective response will be determined for each patient based on the best response recorded from start of study treatment to end of treatment, including any assessments for confirmation after the end of treatment using RECIST 1.1.

    Time frame: From first dose to confirmed progressive disease (approximately 1 year)

  15. Objective response rate

    Objective response rate is defined as the percentage of patients who have at least one response of CR or PR prior to any evidence of progression (as defined by RECIST 1.1) that is confirmed at least 4 weeks later.

    Time frame: From first dose to confirmed progressive disease (approximately 1 year)

  16. Percentage change in tumour size

    Percentage change in tumour size will be determined for patients with measurable disease at baseline and is derived at each visit by the percentage change from baseline in the sum of the diameters of TLs. The best percentage change in tumour size will be the patient's value representing the largest decrease (or smallest increase) from baseline in tumour size using RECIST 1.1.

    Time frame: From first dose to confirmed progressive disease (approximately 1 year)

  17. Durable response rate

    Duration of response will be defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression, the end of response should coincide with the date of progression or death from any cause used for the PFS endpoint using RECIST 1.1.

    Time frame: From first documented response to confirmed progressive disease (approximately 1 year)

  18. Progression free survival

    Progression free survival (PFS) is defined as the time from start of treatment (first dose of ceralasertib) until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the subject withdraws from therapy or receives another anti-cancer therapy prior to progression using RECIST 1.1.

    Time frame: From first dose to confirmed progressive disease (approximately 1 year)

  19. Survival assessment /status

    Module 2 only. To be obtained for all patients who received ceralasertib and olaparib in part A2, B1, B2, B3, B4 and B5.

    Time frame: From first dose to confirmed progressive disease (approximately 1 year)

  20. Module 4: Safety and tolerability in terms of AE and SAE as recorded in safety measures

    Safety measures: AEs assessments (CTCAE grading)

    Time frame: From baseline until 28 days after discontinuation of study treatment for Module 4 Part B cohort 1 and cohort 3, or until 90 days after discontinuation of study treatment for Module 4 Part B cohort 2

  21. Module 4 only: Effect of food on ceralasertib absorption by Cmax in a fasted and fed state (Part A)

    Intensive PK sampling at defined timepoints to measure geometric mean and 90% CI for the ratio of fed: fasted in Cmax - Maximum plasma concentration (Cmax)

    Time frame: Part A (Cycle 0 Day 2/Day 8/Day 15) - each cycle is of 15 days

  22. Module 4 only: Effect of food on ceralasertib absorption by Tmax in a fasted and fed state (Part A)

    Intensive PK sampling at defined timepoints to measure geometric mean and 90% CI for the ratio of fed: fasted in Tmax - time to reach maximum plasma concentration (Tmax)

    Time frame: Part A (Cycle 0 Day 2/Day 8/Day 15) - each cycle is of 15 days

  23. Module 4 only: Effect of food on ceralasertib absorption by clearance in a fasted and fed state (Part A)

    Intensive PK sampling at defined timepoints to measure geometric mean and 90% CI for the ratio of fed: fasted in apparent clearance following oral administration (CL/F)

    Time frame: Part A (Cycle 0 Day 2/Day 8/Day 15) - each cycle is of 15 days

  24. Module 4 only: Effect of food on ceralasertib absorption by apparent volume of distribution in a fasted and fed state (Part A)

    Intensive PK sampling at defined timepoints to measure geometric mean and 90% CI for the ratio of fed: fasted in apparent volume of distribution (Vz/F)

    Time frame: Part A (Cycle 0 Day 2/Day 8/Day 15) - each cycle is of 15 days

  25. Module 4 only: Effect of food on ceralasertib absorption by terminal half-life and terminal rate constant in a fasted and fed state (Part A)

    Intensive PK sampling at defined timepoints to measure geometric mean and 90% CI for the ratio of fed: fasted in terminal rate constant (λz), and terminal half-life (t1/2)

    Time frame: Part A (Cycle 0 Day 2/Day 8/Day 15) - each cycle is of 15 days

  26. Module 4: The number of subjects with adverse events/serious adverse events

    Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal vital signs, and abnormal laboratory assessments that changed from baseline

    Time frame: From baseline until 28 days after discontinuation of study treatment for Module 4 Part B cohort 1 and cohort 3, or until 90 days after discontinuation of study treatment for Module 4 Part B cohort 2

  27. Module 5 only: Maximum Observed Plasma Concentration (Cmax) of AZD5305

    Blood samples will be collected to assess plasma concentration of AZD5305 at a series of time points to derive Cmax.

    Time frame: At predefined intervals throughout AZD5305 treatment period (approximately 8 weeks + IP disc)

  28. Module 5 only: Time to observed Cmax (Tmax) for AZD5305

    Blood samples will be collected to assess plasma concentration of AZD5305 at a series of time points to derive Tmax.

    Time frame: At predefined intervals throughout AZD5305 treatment period (approximately 8 weeks + IP disc)

  29. Module 5 only: Area under the plasma concentration-time curve (AUC) for AZD5305

    Blood samples will be collected to assess plasma concentration of AZD5305 at a series of time points to derive AUC.

    Time frame: At predefined intervals throughout AZD5305 treatment period (approximately 8 weeks + IP disc)

07

Study locations

28 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Irvine, California 92618, United States
  • Research Site
    Los Angeles, California 90024, United States
  • Research Site
    Los Angeles, California 90089, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Lyon, 69373, France
  • Research Site
    Saint-Herblain, 44805, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Goyang-si, 10408, South Korea
  • Research Site
    Seongnam-si, 13620, South Korea
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Bristol, BS2 8ED, United Kingdom
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site
    Coventry, CV2 2DX, United Kingdom
  • Research Site
    London, SW3 6JJ, United Kingdom
  • Research Site
    London, W12 0HS, United Kingdom
  • Research Site
    London, W1G 6AD, United Kingdom
  • Research Site
    London, W1T 7HA, United Kingdom
  • Research Site
    Manchester, M20 4GJ, United Kingdom
  • Research Site
    Oxford, OX3 7LE, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
  • Research Site
    Withington, M20 4BX, United Kingdom
08

References and documents

Publications

  • Lopez JS, Harrington KJ, Im SA, Lee KW, Postel-Vinay S, Thomas JS, Lukashchuk N, Willis SE, Irurzun-Arana I, Webb B, Nehra J, Lau A, Loembe AB, Dean E, Krebs MG. Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC. Br J Cancer. 2026 Jun;134(11):1568-1579. doi: 10.1038/s41416-026-03408-y. Epub 2026 Mar 31. PubMed 41917211 ↗
  • Smith G, Alholm Z, Coleman RL, Monk BJ. DNA Damage Repair Inhibitors-Combination Therapies. Cancer J. 2021 Nov-Dec 01;27(6):501-505. doi: 10.1097/PPO.0000000000000561. PubMed 34904813 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Mar 2025, 124 months.

Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 124 months is above that.

Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2014
First posted
Oct 15, 2014
StartActual
Oct 31, 2014
Primary completionActual
Mar 4, 2025
CompletionEst.
Dec 30, 2026
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02264678
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 15, 2014
Start date
Oct 31, 2014
Primary completion
Mar 4, 2025
Completion
Dec 30, 2026 (estimated)
Last update
Jul 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Ceralasertib

Start the discussion